anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The management of anoperineal suppurations of Crohn's disease is most often based on clinical practice recommendations, the results of randomized controlled trials and also the analysis of monocentric cohort studies from expert centres. In these latter studies, there is an overall improvement in patients during follow-up with a high level of satisfaction (two thirds of cases), often assessed by the operator himself or the clinician who provides therapeutic management. The most striking finding is the one that highlights the use of combined therapeutic strategies combining immunosuppressants, biotherapies, antibiotics, surgical drainage and surgical reconstruction procedures to varying degrees. Thus, the absence of fistula pathway flow in the long term is the consequence of both maintenance treatment with biotherapies and several surgical procedures. When the characteristics of fistula pathways considered healed on clinical examination are analysed by MRI exploration, an active unhealed pathway persists in two thirds of cases, again emphasizing the inadequacy of clinical examination as a means of assessing recovery. For this reason, fistula pathway closure strategies do not provide much greater benefit than simple removal of the drainage loop. Conversely, medical treatment optimization strategies based on MRI evaluation of the therapeutic response have demonstrated high efficacy. It is necessary to (re)define the therapeutic management of patients with anoperineal lesions. This strategy must be based on a better initial stratification of patients based on prognostic factors derived from available scientific data. A second step consists in setting therapeutic efficacy objectives that take into account the control of the inflammatory component of anal Crohn's disease and the preservation of the anatomical and functional capital of the anus. Only a large prospective cohort at the national level provides the opportunity to study these prognostic factors and to specify the level of optimal therapeutic responses
Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria.  Magnetospirillum magneticum  AMB-1 produces positive MRI contrast when generating ultrasmall magnetite particles (10-40 nm diameter). Positive MRI contrast permits clearer distinction from image voids compared to negative contrast. T1-weighted MRI showed that such bacteria increased positive contrast 2.2-fold (p<0.02) in vitro and 2.0-fold (p<0.02) following intratumoral injection in mouse tumor xenografts. Upon intravenous delivery,  Magnetospirillum magneticum  AMB-1 targeted tumors and generated increased positive MRI contrast in them (1.4-fold; p<0.01). AMB-1 tumor targeting was shown by viable counts, microPET imaging of radio-labeled AMB-1, and Prussian blue staining of tumor sections. Thus, magnetotactic bacteria provide a tool for improving cancer diagnosis and monitoring treatment response by MRI.
A tablet easily enabling the suppression of the occurrence of loss at low cost without increasing the hardness thereof even if the tablet receives a stress during transportation, packaging by an automatic packer, or taking out from a PTP and the easy increase of productivity. The tablet comprises a body part (2) with a prescribed thickness and cap parts (3) swelled from the upper and lower faces (4) on the upper and lower sides thereof in protruded shapes. The surfaces of the peripheral edge parts (7) of the cap parts (3) comprise rise angles (.alpha.) of 35 to 50~ relative to the upper and lower faces (4) of the body part (2), and their cross sections are formed in circular arc-shaped projected curved surfaces. The surfaces of the cap parts (3) comprise angles (.beta.) of 20~ or more relative to the upper and lower faces (4) at positions (9) apart a length (L) equivalent to 5% of the horizontal length (D) of the body part (2) from the peripheral edge of the body part (2) to the inside. The surfaces of the peripheral edge parts (7) are smoothly connected to the surfaces of the center part (6) thereof.
The subject invention pertains to materials and methods for stopping or decreasing the blood flow from an open wound or medical or surgical procedure. Compositions of the invention comprise a salt form of a cross-linked polyacrylic acid. In one embodiment, the composition comprises a sodium salt of a polyacrylic acid. Compositions of the invention can also optionally comprise one or more different salt ferrates, and/or a cationic exchanger resins, and/or a silver compound, hi an exemplified embodiment, a composition of the invention comprises sodium polyacrylate provided in a dry powdered form. Polyacrylate compositions of the invention can be applied directly to a wound or treatment site, or they can be incorporated into a wound dressing, such as a bandage. The clot or scab formed at a wound or treatment site treated with the present invention is extremely elastic and exhibits considerable tensile strength when stretched to the breaking point. The subject invention also concerns wound and surgical site dressings and coverings, and methods of using a composition of the invention to stop blood flow from an open wound or treatment site.
In the first phase of the study, a three-day workshop (20 hours) online training on DBT-SUD intervention will be provided to professionals. In the second phase, participants will implement DBT-SUD in group that will consist of applying the skills training mode of DBT for 3 months (12-14 sessions, two hours each). Regarding the specific contents, they will be based on the program published by Maffei´s team (DBT certified trainer and therapist in Italy), which has shown good results in improving the severity and frequency of alcohol use and emotional dysregulation with a 3-month program. Four modules of the skills training program will be applied: mindfulness, distress tolerance, skills to deal with addiction and emotional regulation skills. A self-management and rehabilitation module will be also included.
Total knee replacement is a common surgical procedure that restores function to the damaged joint. Recovery from this procedure takes weeks and requires opioids to manage post-surgical pain. The goal of this study is to investigate whether dronabinol (synthetic THC) can reduce pain and the need for opioid medication following this particular surgery.

Subjects will be recruited from the Department of Orthopedic Surgery. All subjects will undergo total knee replacement as part of their clinical care (the surgery itself is not part of this study). The study begins following discharge from the hospital. They will be asked to take dronabinol or placebo as they recover from surgery. During this time they will be given their usual pain medications at discharge which includes opioids for pain. The opioids are to be taken if the subject is experiencing pain. The investigator's hypothesis is that subjects taking dronabinol will need fewer doses of opioids to control pain.
PROBLEM TO BE SOLVED: To obtain an excellent hair cosmetic that has no fear in aspect of safety by formulating an plant extract obtained by extraction of a specific plant of chrysanthemum family and optionally a ferrous or ferric salt or tannin or tannic acid. SOLUTION: This cosmetic contains an extract obtained by extraction from Eclipta alba Hassk of chrysanthemum family. Furthermore, a ferric or ferrous salt, together with or without Chinese gallotannin or gallotannic acid, is optionally formulated into the extract. The content of Eclipta alba Hassk extract added to the cosmetic is in a range of 0.1-20wt.% to the total weight of the cosmetic. The content of the ferrous or ferric salt is sufficient in the amount of 0.01-1.0wt.%. The content of Chinese gallotannin or gallotannic acid is in a range of 1.1-2.0wt.% to total weight of the cosmetic. This cosmetic has effects of improving hair-touch feeling on the sound hair and furthermore on the damaged hair by recovering the hair from the damage, also causing no staining of pillowcases, etc.
Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
OBJECTIVES: Despite evidence of increased incidence of early-onset pancreatic cancer (EOPC), defined as pancreatic cancer diagnosed in patients below 50 years old, and its risk factors in the Western region, global epidemiological data addressing this issue is still lacking.
MATERIALS AND METHODS: Utilizing data from the Global Burden of Disease Study 2019, we aimed to conduct a comprehensive analysis of the incidence, deaths, and disability-adjusted life years (DALYs) associated with EOPC and its risk factors, including smoking, obesity, and diabetes. The analysis examined the annual percentage change (APC) over the period.
RESULTS: In 2019, the incidence of EOPC surpassed 35,000 cases worldwide. This burden of EOPC tends to be more prevalent in males, as well as in Europe and high SDI countries. However, there is a noticeable upward trend in the burden of EOPC in the Eastern Mediterranean. While there is a global decline in EOPC mortality attributed to smoking (APC -0.33%), there is a concerning increase in mortality associated with diabetes (APC +2.84%) and obesity (APC +2.12%).
CONCLUSIONS: The burden of EOPC has been increasing. The mortality is rising mainly from metabolic factors. There is an urgent need for national policy development for reducing the burden of this disease.
Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
In this arm, the subjects will receive the intervention of FSN combined with regular rehabilitation program on Day1, Day2, and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
Oral pharmacologic agents have been the primary option, and the use of drugs has increased exponentially. Many pharmacological agents have been used to manage endodontic pain, including Non-steroidal Anti-inflammatory Drugs (NSAIDs),.administration of NSAIDs before root canal treatment will reduce inflammatory process before it begins. NSAIDs are widely used to control post endodontic pain They act by blocking the activity of cyclooxygenase (COX 1 and 2) enzyme. In human dental pulps with irreversible pulpitis, a higher level of expression of COX 2.In cases of irreversible pulpitis NSAIDS can be administered preoperatively since they reduce the level of prostaglandinE2(PGE2) which is responsible for sensitization of nociceptors. Ibuprofen is one of the most commonly used NSAIDs and a potent inhibitor of prostaglandin (PG) synthesis that can manage various pain types and has anti-inflammatory activity. Enhancements in ibuprofen acid's pharmacokinetics have led to the development of ibuprofen salts with a faster dissolution rate and onset of action. These ibuprofen salts.Fast acting ibuprofen like Sodium ibuprofen delivers maximum plasma drug concentrations at about 30-40 min, compared with around 90-120 min for standard ibuprofen acid formulations
Papular acne scars are a special type of acne scar, and the prevalence and treatment of this disease have rarely been reported in the literature; moreover, the prevalence of this disease is often neglected, and treatment is difficult. Our study revealed a high prevalence of this type of acne scar in the clinic and explored an effective and safe method. This retrospective study aimed to analyse the prevalence of papular acne scarring among patients attending our Dermatology Laser Clinic and evaluate the clinical efficacy of fractional CO2 lasers. We retrieved the data of 370 patients with acne scarring who visited our hospital between April 2021 and November 2022 and analysed the prevalence of papillary acne scarring among them. Among these patients, 35 underwent CO2 laser treatment using an artificial grid pattern. A total of three treatments were administered, with a two-month interval between each session. Scar assessment was conducted using the Global Scar Scale (GSS) and the Acne Scar Clinical Assessment (ECCA) scale, along with physician visual evaluation and patient satisfaction surveys, both before the first treatment and one month after the final treatment. Adverse reactions were recorded during follow-up visits after each treatment. Among the 370 patients with acne scarring, 128 exhibited papular acne scarring, resulting in a prevalence rate of 34.6%. Among them, 37.5% were male and 32.6% were female. A total of 90.6% of patients had combined other types of acne scarring, while 9.4% had papular acne scarring exclusively. Following CO2 laser grid treatment, there was a significant reduction in GSS scores and ECCA values, accompanied by a noticeable improvement in physician visual evaluation and patient satisfaction scores. Papular acne scarring has a relatively high incidence rate, and there is no significant sex difference. It often coexists with other types of acne scarring. CO2 laser treatment using an artificial grid pattern effectively improved papular acne scarring with a good safety profile.
Taste modifier products and therapeutic methods for encouraging decrease in high calorie food intake by a person are disclosed. A taste modifier product ingested toy a person may comprise one or more sweetness inhibitors and one or more anesthetics. The taste modifier product may decrease sensitivity to sweet and bitter tastes when the product is ingested by the person. One or more coolant ingredients may also be included in a taste modifier product. The ingredients of a taste modifier product may be incorporated into a lozenge, a beverage, a chewing gum, an oral spray, an oral powder, a hard or a soft candy, a dessert or a foodstuff. When consumed by a person, the products may both depress a person's appetite and relieve hunger symptoms. Consequently, a person consuming the products may select smaller portion sizes when eating food and limit high calorie foods.
Pregnant women exposed to polycyclic aromatic hydrocarbons (PAHs) are at increased risk for premature delivery. Premature infants often require supplemental oxygen, a known risk factor for bronchopulmonary dysplasia (BPD). Cytochrome P450 (CYP) enzymes have been implicated in hyperoxic lung injury. We hypothesize that prenatal PAH exposure exacerbates oxygen-mediated lung injury in neonatal mice, and that this effect is differentially altered in mice lacking the gene for (Cyp)1a1, 1a2, or 1b1. Timed pregnant wild type (WT) (C57BL/6J) mice were orally administered a PAH mixture of benzo[a]pyrene (BP) and benzo[b]fluoranthene (BbF) or the vehicle corn oil (CO) once daily on gestational days 16-19, and the dose response on postnatal lung injury was examined. In addition, timed pregnant mice with one of four genotypes, WT, Cyp1a1-null, Cyp1a2-null, and Cyp1b1-null, were treated orally with CO or PAH on gestational days 16-19 and exposed to hyperoxia or room air for 14 days. Lung injury was assessed on PND15 by radial alveolar count (RAC) and mean linear intercept (MLI) Gene expression of DNA repair genes in lung and liver were measured. Results showed that neonatal hyperoxic lung injury is augmented by prenatal PAH exposure in a dose-dependent manner. This effect was differentially altered in the Cyp-null mice, with Cyp1a2-null showing the greatest extent of lung injury. We concluded that newborn mice exposed to PAH in utero had more significant lung injury in response to hyperoxia than non-PAH exposed pups, and that CYP1A1 and CYP1A2 are protective against lung injury while CYP1B1 augments lung injury.
Pseudorabies virus is a swine alpha-herpesvirus. We demonstrated that alpha-herpesvirus infection downregulates HSF1, a master transcription factor in the heat shock response. The serine/threonine protein kinase activity of late viral protein UL13 is indispensable for HSF1 depletion and phosphorylation, and UL13 does not degrade HSF1 posttranslationally but inhibits the HSF1 mRNA level. Importantly, UL13 increased HSF1 activity even though it reduced HSF1 mRNA. Furthermore, viral replication markedly decreased in the HSF1 knockout cell line or in the presence of an HSF1-specific inhibitor. Interestingly, HSF1 knockout accelerated the activation of NF-κB and p38MAPK. The K96 loci of UL13 are important to induce high levels of IL-6, TNF-α, and IL-β cytokines while playing a crucial role in promoting mild interstitial pneumonia, liver necrosis, and severe inflammatory cell infiltration in the footpad. Thus, UL13 steers the heat shock response to promote viral replication and the inflammatory response. IMPORTANCE: PRV is a ubiquitous pathogen that infects a variety of mammals, such as pigs, ruminants, carnivores, and rodents as well as human beings, causing enormous economic losses in the swine industry. Here, we employed PRV as a model to determine the relationship between α-herpesvirus and the inflammatory response. Overall, our findings indicated that PRV infection inhibits the level of HSF1 mRNA via the serine/threonine protein kinase activity of UL13. Additionally, we discovered that HSF1 was involved in NF-κB activation upon PRV infection. PRV UL13 orchestrates the level of HSF1 mRNA, HSF1 protein phosphorylation, and priming of the inflammatory response. Our study reveals a novel mechanism employed by UL13 serine/threonine protein kinase activity to promote the inflammatory response, providing novel clues for therapy against alpha-herpesvirus infection.
PROBLEM TO BE SOLVED: To obtain a new compound having a selective affinity for especially Y5 receptor among neuropeptide Y receptors and useful for feeding control and for prophylactics and/or treatments of diabetes, hypercholesterolemia, hyperlipemia, etc. SOLUTION: This compound is a compound of formula I (R1 to R4 are each H or a lower alkyl and R1 and R2, and R3 and R4 can respectively form rings by binding to each other; and X is oxygen or sulfur). The compound of formula I is obtained, for instance, by reacting a compound of formula II (e.g. 3- hydroxy-2-thiophenecarboxyaldehyde) with a compound of formula III (e.g. Dimedon) followed by reacting the resultant product with a compound of formula IV. It is preferable to use about 1.5-3 mol of each compound of formulas III and IV per mol of the compound of formula II in the above reactions. The reaction temperature and time of the above reactions are preferably 50-150 deg.C and 1-6 h.
The present invention provides topical, non-aqueous pharmaceutical compositions containing about 10 % to about 80 % W/W of a pharmaceutically acceptable noncomedogenic cosmetic oil and ethanol or isopropanol. The compositions provided for improved stability and delivery of the drug to the site of action (e.g. hair follicle and sebaceous gland) without excessive greasiness and/or untoward drying effects. The compositions are also provided for an anti-inflammatory effect and reduced irritation when clindamycin is used in combination with retinoids. The topical pharmaceutical compositions of the present invention can optionally contain propylene glycol and/or polyethylene glycol and/or a pharmaceutically acceptable organic amine. In addition, the topical pharmaceutical compositions of the present invention can optionally be gelled with suitable gelling agents, including for example hydroxypropylcellulose.
BACKGROUND: Inflammatory bowel disease (IBD) is characterized by chronic progressive intestinal inflammation. Sacral nerve stimulation (SNS) ameliorates colon inflammation caused by IBD. The aim of this study was to investigate the antiinflammatory benefits of SNS in colitis rats and explore the roles of the cholinergic antiinflammatory pathway, macrophage autophagy, and nucleotide oligomerization domain-like receptor thermal protein domain associated protein 3 (NLRP3) inflammatory bodies.
MATERIALS AND METHODS: Rats were divided into four groups: healthy control, dextran sulfate sodium (DSS), DSS + sham-SNS, and DSS + SNS groups. An electrode was surgically placed in the right sacral nerve (S3) for stimulation. The disease activity index (DAI) score was recorded each day, and the degree of inflammatory injury was evaluated using hematoxylin and eosin staining. The alpha7 nicotinic acetylcholine receptor (α7nAChR) and autophagy- and NLRP3-related factors were assessed using immunofluorescence staining and Western blotting.
RESULTS: The DSS group showed a higher DAI score, colon shortening, upregulated proinflammatory action, and colon damage, and the DSS + SNS group showed significantly improved symptoms. The number of α7nAChR+ cells and the expression level of autophagy decreased in the DSS group but increased in the DSS + SNS group. Conversely, the DSS group showed increased activation of NLRP3 inflammatory bodies, whereas the DSS + SNS group showed decreased activation of NLRP3 inflammatory bodies.
CONCLUSION: In this study, SNS ameliorated colon inflammation by enhancing macrophage autophagy and inhibiting the activation of NLRP3 inflammatory bodies, which may be related to the opening of the cholinergic antiinflammatory pathway.
Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
Significant naproxen overdosage may be characterized by lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, transient alterations in liver function, hypoprothrombinemia, renal dysfunction, metabolic acidosis, apnea, disorientation or vomiting. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. Because naproxen sodium may be rapidly absorbed, high and early blood levels should be anticipated. A few patients have experienced convulsions, but it is not clear whether or not these were drug-related. It is not known what dose of the drug would be life-threatening. The oral LD50 of the drug is 543 mg/kg in rats, 1234 mg/kg in mice, 4110 mg/kg in hamsters, and greater than 1000 mg/kg in dogs.
Title cpds. of formula (I): (where R1, R2 and R3 are H, lower (i.e. 1-5C) alkyl, lower alkoxy or OH and R4 is H or lower alkyl), which are pharmaceutically active, particularly against cardiac and circulatory disorders, are prepd. by hydrogenating corr. phenethylamino-acrylophenones in an organic solvent other than a lower aliphatic alcohol or ester thereof. Racemic products may be optically resolved, stereochemically uniform products may also be obtained by using stereochemically uniform starting materials.